As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity decreases, scans show improvement, and patient lifespans are prolonged for some ...
Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...
A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.
Successful induction of tumor-directed immune responses in high grade serious ovarian carcinoma patients after primary treatment using a whole tumor cell vaccine. Real-world analysis of folate ...
Add Yahoo as a preferred source to see more of our stories on Google. As treatment sequencing in ovarian cancer (OC) continues to evolve, an increasing proportion of patients acquire ...
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast ...
Ways to accelerate the local implementation and adoption of the homologous recombination deficiency (HRD) testing in India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results